我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 ONO PHARMACEUTICAL CO., LTD.
相关临床试验
15
3 进行中
药物批准
1
批准总数
监管机构
监管机构数
成立时间
2003
进行中（未招募）
3
20.0%
招募中
12
80.0%
EMC
Electronic Medicines Compendium
- Ono Pharmaceutical expanded its collaboration with Congruence Therapeutics in March 2026 to include neurology and immunology drug discovery, extending beyond their previous oncology focus. - The company secured exclusive worldwide option rights over small molecule candidates developed through Congruence's Revenir computational platform in these new therapeutic areas. - Ono also partnered with Sinopia Biosciences on rare metabolic disorders while implementing operational changes including transferring Forxiga distribution back to AstraZeneca. - These strategic moves represent Ono's broader push to diversify its pipeline into areas of significant unmet medical need through AI-driven external collaborations.
